

Resource Summary Report

Generated by PRECISE-TBI on Jul 31, 2026

C57BL/6JGpt-H11^{em1Cin(K18-hACE2)}/Gpt

RRID:IMSR_GPT:T037657

Type: Organism

Proper Citation

RRID:IMSR_GPT:T037657

Organism Information

URL: https://en.gempharmatech.com/product/details100035_3719035.html

Proper Citation: RRID:IMSR_GPT:T037657

Description: Mus musculus with name C57BL/6JGpt-H11^{em1Cin(K18-hACE2)}/Gpt from IMSR.

Species: Mus musculus

Notes: gene symbol note: angiotensin I converting enzyme 2; coisogenic strain: ACE2;H11

Affected Gene: angiotensin I converting enzyme 2

Catalog Number: GPT:T037657

Database: GemPharmatech

Database Abbreviation: GPT

Availability: embryo

Organism Name: C57BL/6JGpt-H11^{em1Cin(K18-hACE2)}/Gpt

Record Creation Time: 20250513T054339+0000

Record Last Update: 20260725T044946+0000

Ratings and Alerts

No rating or validation information has been found for C57BL/6JGpt-H11^{em1Cin(K18-hACE2)}/Gpt.

No alerts have been found for C57BL/6JGpt-H11^{em1Cin(K18-hACE2)}/Gpt.

Data and Source Information

Source: [Integrated Animals](#)

Source Database: GemPharmatech

Usage and Citation Metrics

We found 411 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Wang M, et al. (2026) Impaired VLCFA-peroxisome-mediated intestinal epithelial repair causes gastrointestinal sequelae of long COVID. *Developmental cell*.

Jeong H, et al. (2025) Post-COVID-19 Effects on Chronic Gastritis and Gastric Cellular and Molecular Characteristics in Male Mice. *Cellular and molecular gastroenterology and hepatology*, 19(8), 101511.

Counoupas C, et al. (2025) An adjuvanted chimeric spike antigen boosts lung-resident memory T-cells and induces pan-sarbecovirus protective immunity. *NPJ vaccines*, 10(1), 89.

Gontu A, et al. (2025) Trans amplifying mRNA vaccine expressing consensus spike elicits broad neutralization of SARS CoV 2 variants. *NPJ vaccines*, 10(1), 110.

Yin X, et al. (2025) Global siRNA screen identifies human host factors critical for SARS-CoV-2 replication and late stages of infection. *PLoS biology*, 23(6), e3002738.

Shuai H, et al. (2025) An orally available Mpro/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivo. *Nature communications*, 16(1), 6541.

Mo C, et al. (2025) Adenovirus Nanoparticles Displaying RBD Induce a Protective Immune Response Against BA.5 in Mice. *International journal of nanomedicine*, 20, 9771.

Kenney D, et al. (2025) Comprehensive Analysis of the Impact of Weight Loss Thresholds on Mouse Models of Fatal Viral Infection. *Viruses*, 17(9).

Lin Y, et al. (2025) Sequential intranasal booster triggers class switching from intramuscularly primed IgG to mucosal IgA against SARS-CoV-2. *The Journal of clinical investigation*, 135(5).

Selvaraj P, et al. (2025) Differential patterns of cross-protection against antigenically distinct variants in small animal models of SARS-CoV-2 infection. *Npj viruses*, 3(1), 49.

Nunes JPDS, et al. (2025) Adjuvant combination and antigen multimerization shape neutralizing antibody and T cell responses to a SARS-CoV-2 RBD subunit vaccine. *Frontiers in immunology*, 16, 1610422.

Bobrow B, et al. (2025) Identification of HIF1A as a therapeutic target during SARS-CoV-2-associated lung injury. *JCI insight*, 10(14).

Kim CW, et al. (2025) Differential responses of lung and intestinal microbiota to SARS-CoV-2 infection: a comparative study of the Wuhan and Omicron strains in K18-hACE2 Tg mice. *Laboratory animal research*, 41(1), 11.

Stephens EB, et al. (2025) The Role of the Tyrosine-Based Sorting Signals of the ORF3a Protein of SARS-CoV-2 in Intracellular Trafficking and Pathogenesis. *Viruses*, 17(4).

Halfmann PJ, et al. (2025) Potent bivalent nanobody constructs that protect against the SARS-CoV-2 XBB variant. *Npj viruses*, 3(1), 19.

Jiao Y, et al. (2025) In Vivo Iterative Adjuvant Screening Identifies an Intranasal Vaccine Formulation for Elicitation of Protective Mucosal Immune Responses Against SARS-CoV-2. *Pharmaceutics*, 17(11).

Lakhrif Z, et al. (2025) Intranasal spike and nucleoprotein fusion protein-based vaccine provides cross-protection and reduced transmission against SARS-CoV-2 variants. *NPJ vaccines*, 10(1), 75.

Zhang C, et al. (2025) Host protein ARF1 is a proviral factor for SARS-CoV-2 and a candidate broad-spectrum therapeutic target. *Nature communications*, 16(1), 6326.

Idris A, et al. (2025) Intranasal delivery of engineered anti-SARS-CoV-2 extracellular vesicles therapeutically represses lung infection and inflammation. *Drug delivery and translational research*, 15(11), 4115.

Gerzanich V, et al. (2025) COVID-19-associated neuroinflammation and astrocyte death in the brain linked to ORF3a-induced activation of Sur1-mediated ion channels. *mBio*, 16(9), e0201225.